Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
VANCOUVER, British Columbia, Aug. 02, 2017 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox President & CEO, will present a corporate overview at the upcoming Canaccord Genuity 37th Annual Growth Conference in New York, NY on Wednesday, August 9th 2017 at 5:00 PM Eastern Time.
A live audio webcast and archive of the event will be available at: http://wsw.com/webcast/canaccord26/aqxp
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a late clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. In September 2016, we began enrolling patients in a Phase 3 clinical trial of AQX-1125 in our lead indication, Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Other indications are under consideration for future investigation. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Associate Director, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
